388 related articles for article (PubMed ID: 16772708)
1. Effect of erythropoietin on urinary liver-type fatty-acid-binding protein in patients with chronic renal failure and anemia.
Nakamura T; Sugaya T; Kawagoe Y; Suzuki T; Ueda Y; Koide H
Am J Nephrol; 2006; 26(3):276-80. PubMed ID: 16772708
[TBL] [Abstract][Full Text] [Related]
2. Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy.
Nakamura T; Sugaya T; Node K; Ueda Y; Koide H
Am J Kidney Dis; 2006 Mar; 47(3):439-44. PubMed ID: 16490622
[TBL] [Abstract][Full Text] [Related]
3. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
4. Urinary excretion of fatty acid-binding proteins in idiopathic membranous nephropathy.
Hofstra JM; Deegens JK; Steenbergen EJ; Wetzels JF
Nephrol Dial Transplant; 2008 Oct; 23(10):3160-5. PubMed ID: 18403431
[TBL] [Abstract][Full Text] [Related]
5. Renovascular protective effects of erythropoietin in patients with chronic kidney disease.
Fujiwara N; Nakamura T; Sato E; Kawagoe Y; Hikichi Y; Ueda Y; Node K
Intern Med; 2011; 50(18):1929-34. PubMed ID: 21921371
[TBL] [Abstract][Full Text] [Related]
6. Metabolic effects of keto acid--amino acid supplementation in patients with chronic renal insufficiency receiving a low-protein diet and recombinant human erythropoietin--a randomized controlled trial.
Teplan V; Schück O; Votruba M; Poledne R; Kazdová L; Skibová J; Malý J
Wien Klin Wochenschr; 2001 Sep; 113(17-18):661-9. PubMed ID: 11603100
[TBL] [Abstract][Full Text] [Related]
7. Factor deficiency in the anemia of renal transplant patients with grade III-IV chronic kidney disease: baseline results of the ARES Study.
Gentil MA; Pérez-Valdivia MA; López-Mendoza M; Ortega F; Arias M; Gómez-Alamillo C; Campistol JM;
Transplant Proc; 2008 Nov; 40(9):2922-4. PubMed ID: 19010148
[TBL] [Abstract][Full Text] [Related]
8. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy.
Nakamura T; Sugaya T; Kawagoe Y; Ueda Y; Osada S; Koide H
Diabetes Care; 2005 Nov; 28(11):2728-32. PubMed ID: 16249547
[TBL] [Abstract][Full Text] [Related]
9. Oral adsorbent AST-120 ameliorates tubular injury in chronic renal failure patients by reducing proteinuria and oxidative stress generation.
Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Suzuki T; Ueda Y; Yamagishi S
Metabolism; 2011 Feb; 60(2):260-4. PubMed ID: 20189611
[TBL] [Abstract][Full Text] [Related]
10. Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease.
Nakamura T; Sugaya T; Kawagoe Y; Suzuki T; Inoue T; Node K
Am J Nephrol; 2006; 26(1):82-6. PubMed ID: 16534182
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.
Palazzuoli A; Silverberg D; Iovine F; Capobianco S; Giannotti G; Calabrò A; Campagna SM; Nuti R
Am Heart J; 2006 Dec; 152(6):1096.e9-15. PubMed ID: 17161060
[TBL] [Abstract][Full Text] [Related]
12. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
13. Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis.
Hall AM; Edwards SG; Lapsley M; Connolly JO; Chetty K; O'Farrell S; Unwin RJ; Williams IG
Am J Kidney Dis; 2009 Dec; 54(6):1034-42. PubMed ID: 19783343
[TBL] [Abstract][Full Text] [Related]
14. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
15. Effect of red wine on urinary protein, 8-hydroxydeoxyguanosine, and liver-type fatty acid-binding protein excretion in patients with diabetic nephropathy.
Nakamura T; Fujiwara N; Sugaya T; Ueda Y; Koide H
Metabolism; 2009 Aug; 58(8):1185-90. PubMed ID: 19481229
[TBL] [Abstract][Full Text] [Related]
16. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
17. Treatment of anemia in renal transplantation: impact of a stricter application of hemoglobin targets.
Gentil MA; Pérez-Valdivia MA; González-Roncero FM; López-Mendoza M; Cabello V; Bernal G; Suñer M; Pereira P
Transplant Proc; 2008 Nov; 40(9):2916-8. PubMed ID: 19010146
[TBL] [Abstract][Full Text] [Related]
18. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL.
Ayus JC; Go AS; Valderrabano F; Verde E; de Vinuesa SG; Achinger SG; Lorenzo V; Arieff AI; Luño J;
Kidney Int; 2005 Aug; 68(2):788-95. PubMed ID: 16014057
[TBL] [Abstract][Full Text] [Related]
19. The prevalence of anemia in patients with chronic kidney disease.
McClellan W; Aronoff SL; Bolton WK; Hood S; Lorber DL; Tang KL; Tse TF; Wasserman B; Leiserowitz M
Curr Med Res Opin; 2004 Sep; 20(9):1501-10. PubMed ID: 15383200
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.
Nakamura T; Inoue T; Sugaya T; Kawagoe Y; Suzuki T; Ueda Y; Koide H; Node K
Am J Hypertens; 2007 Nov; 20(11):1195-201. PubMed ID: 17954367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
